A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

NCT05116891 PHASE1, PHASE2 COMPLETED

This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).

Details

Lead sponsor	Cantargia AB
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	40
Start date	Wed Sep 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced Solid Tumors
• Colorectal Cancer
• Non Small Cell Lung Cancer
• Biliary Tract Cancer

Interventions

• CAN04 (nadunolimab)
• mFOLFOX
• DTX
• G/C

Countries

France, Spain